Zealand Pharma A/S Stock price

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 10:59:33 2023-12-04 am EST Intraday chart for Zealand Pharma A/S 5-day change 1st Jan Change
340.4 DKK +3.09% +6.31% +69.02%
Sales 2023 * 391M 56.81M Sales 2024 * 1.19B 172M Capitalization 19.85B 2.89B
Net income 2023 * -494M -71.8M Net income 2024 * - 0 EV / Sales 2023 *
45,8x
Net cash position 2023 * 1.93B 281M Net cash position 2024 * 2.8B 407M EV / Sales 2024 *
14,4x
P/E ratio 2023 *
-28,9x
P/E ratio 2024 *
-168x
Employees 249
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.09%
1 week+7.93%
Current month+1.31%
1 month+11.61%
3 months+31.84%
6 months+33.70%
Current year+69.02%
More quotes
1 week
316.60
Extreme 316.6
347.80
1 month
274.40
Extreme 274.4
347.80
Current year
198.00
Extreme 198
347.80
1 year
189.30
Extreme 189.3
347.80
3 years
69.55
Extreme 69.55
347.80
5 years
69.55
Extreme 69.55
347.80
10 years
57.50
Extreme 57.5
347.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 2009
Director of Finance/CFO - Oct. 31
Chief Tech/Sci/R&D Officer - 2020
Members of the board TitleAgeSince
Director/Board Member 65 2019
Chairman 68 2014
Director/Board Member 67 2018
More insiders
Date Price Change Volume
23-12-04 340.4 +3.09% 345,491
23-12-01 330.2 -1.73% 315,124
23-11-30 336 +2.63% 395,391
23-11-29 327.4 +1.99% 158,350
23-11-28 321 +0.25% 354,063

Delayed Quote Nasdaq Copenhagen, December 04, 2023 at 10:59 am EST

More quotes
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Calendar
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
340.4DKK
Average target price
365.33DKK
Spread / Average Target
+7.32%
Consensus
1st Jan change Capi.
+69.02% 2 807 M $
+21.42% 90 488 M $
+14.11% 86 658 M $
-4.62% 34 551 M $
+20.96% 26 777 M $
-33.49% 23 629 M $
-25.33% 20 547 M $
-17.63% 19 529 M $
-2.44% 11 507 M $
+25.50% 10 906 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Zealand Pharma A/S - Nasdaq Copenhagen
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer